Anti TIGIT Antibody Clinical Trials Market Opportunity Insight 2023

Global Anti TIGIT Antibody Clinical Trials and Companies Insight 2023 Report Highlights:

• Global Anti TIGIT Antibodies Market Dynamics
• Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
• Anti TIGIT Antibodies In Clinical Trials : > 45
• Overview On Partnerships and Collaborations In The Global Anti TIGIT Antibodies Market
• Global Anti TIGIT Antibodies Market Outlook
• Competitive Landscape

Download Report: https://www.kuickresearch.com/report-anti-tigit-antibody-antibodies

In the last few decades or so, the development of targeted therapies has seen a boost. These therapies came around as an alternative to conventional treatment methods which were often systematic and untargeted, hence showed adverse effects because of off-target interactions between the drugs and molecules in the body. Especially in the case of cancer, where these interactions lead to many severe, undesirable side effects, targeted therapies emerged and developed as a fourth pillar of treatment. With tedious efforts from researches, several proteins and pathways were discovered which facilitated the development of these diseases. In the recent years, the identification of TIGIT and its role in regulating the immune response has caused it to become one of the newest targets for developing targeted therapies.

TIGIT is an immune checkpoint which means it can downregulate the effects of the immune system. This can have many implications depending on the disease. In cancer, where it is necessary for the body to show a full-fledged immune response towards cancer cells, a working TIGIT immune checkpoint can protect the cancer tumors from the immune cell, enabling their growth. Similarly, in the case of a viral infection, notably HIV, the TIGIT pathway has been implicated in promoting T cell dysfunction and promoting the infection. Contrarily, in autoimmune diseases, where the body’s defense cells actively attack its own cells and tissues and cause unnecessary inflammation, enhancing the TIGIT functions has been shown to provide relief from the pain and the symptoms associated with various autoimmune diseases. Thus, depending on the indication, it becomes important to develop a strategy to smoothly navigate the treatment procedure.

In patients suffering from cancer, TIGIT is frequently overexpressed in tumor-infiltrating immune cells, which partly helps in developing the immunosuppressive surrounding in the tumor microenvironment. Thus the blockade of TIGIT has been extensively studied in various clinical trials over the last 4-5 years. There are many TIGIT inhibitors under development which are being evaluated in clinical trials against several solid and hematological cancers. M6223 (Merck), IBI939 (Innovent) and AB154/domvanalimab (Arcus) are some TIGIT-inhibitors in clinical trials for patients suffering from various forms of solid cancers. In 2021, Tiragolumab, developed by Roche, was granted the Breakthrough Therapy in combination with Atezolizumab for the treatment of patients with metastatic non – small cell lung cancer (NSCLC). This is the first and the only anti-TIGIT therapy with this designation. While Tiragolumab is an anti-TIGIT antibody, Atezolizumab is an anti-PD-1 antibody. The synergic effects of blocking both the TIGIT and PD-1 pathways simultaneously have demonstrated excellent results and have become the top choice for drug developers and clinical researchers alike. Many clinical trials are ongoing which are evaluating the combinatorial effects of anti-TIGIT and anti-PD-1 drugs and have progressed to the second phase of clinical trials. While PD-1 remains a popular second target for these combination therapies, additional checkpoint inhibitors are being evaluated too to improve results.

Though its role has also been connected to the pathogenesis of HIV and treatment of autoimmune disorders, the pace of research and development of anti-TIGIT drugs for these indications has been lethargic. No clinical trials have been reported which are gauging the applicability of these inhibitors for the treatment of viral diseases and autoimmune disorders. The possibility of TIGIT blockage in immunotherapeutic HIV-1 cure techniques has been highlighted by the scope of its effects on T cells and NK cells as well as selectivity for cells where the HIV-1 reservoir is concentrated. While the role of TIGIT in the progression of cancer has gained utmost attention, the entry of investigational drugs in the treatment of cancer has showed their confident safety profile. The experience gained from the development of anti-cancer TIGIT inhibitors can be used further for the development of inhibitors against HIV and autoimmune disorders.

The clinical pipeline for TIGIT inhibitors is increasing with presence of key pharmaceutical companies, including, Novartis, Gilead and Innovent. This has definitely grabbed the attention of other pharmaceutical companies who have reckoned the positive future scope for these inhibitors. Many companies have formed tie-ups with other companies; some are even collaborating with contract research and development organizations to speed up the development of TIGIT inhibitors. There are currently no TIGIT inhibitors in the market and the ones closest to getting the approval are in phase III of trials. The approval of the TIGIT inhibitor is expected to drastically change the clinical landscape and market of targeted cancer therapies. An increase in private and government funding and advance in technology are expected to further boost the market in the near future.

 

Contact:

Neeraj Chawla

Kuick research

Research Head

+91-981410366

neeraj@kuickresearch.com

https://www.kuickresearch.com